Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404

被引：0
|
作者：
Tadahiko Shien
Hiroji Iwata
Takashi Fukutomi
Kenichi Inoue
Kenjiro Aogi
Takayuki Kinoshita
Jiro Ando
Seiki Takashima
Kenichi Nakamura
Taro Shibata
Haruhiko Fukuda
机构：
[1] Okayama University Hospital,Department of Breast and Endocrine Surgery
[2] Aichi Cancer Center Hospital,Department of Breast Oncology
[3] National Cancer Center Hospital,Department of Breast Surgery
[4] Saitama Cancer Center,Department of Medical Oncology
[5] National Hospital Organization Shikoku Cancer Center,Department of Surgery
[6] Tochigi Cancer Center,Department of Breast Surgery
[7] National Cancer Center,JCOG Data Center, Multi
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 74卷
关键词：
Breast cancer; Adjuvant treatment; Node-positive; Premenopausal;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：603 / 609
页数：6
相关论文
共 30 条
  • [21] Adjuvant six cycles of high-dose adriamycin, cyclophosphamide, methotrexate, 5-fluorouracil (ACMF) vs 12 cycles of low-dose ACMF with tamoxifen for premenopausal, node-positive breast cancer patients: Results of a prospective randomized study
    Fukutomi, T
    Akashi, S
    Nanasawa, T
    Yamamoto, H
    JOURNAL OF SURGICAL ONCOLOGY, 1995, 60 (04) : 242 - 246
  • [22] CMF versus tamoxifen plus goserelin as adjuvant treatment of ER-positive pre-perimenopausal breast cancer patients: Preliminary results of an ongoing Italian Breast Cancer Adjuvant Study Group (GROCTA) trial
    Boccardo, F
    Rubagotti, A
    Amoroso, D
    Liquori, M
    Mesiti, M
    Geraci, O
    Delia, P
    Villa, E
    Aldrighetti, D
    Genta, F
    DeSanctis, C
    Irtelli, L
    Donati, D
    Pacini, P
    Farris, A
    Scotto, T
    Schieppati, G
    ADJUVANT THERAPY OF CANCER VIII, 1997, 8 : 101 - 108
  • [23] Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
    Gnant, M.
    Mlineritsch, B.
    Stoeger, H.
    Luschin-Ebengreuth, G.
    Knauer, M.
    Moik, M.
    Jakesz, R.
    Seifert, M.
    Taucher, S.
    Bjelic-Radisic, V.
    Balic, M.
    Eidtmann, H.
    Eiermann, W.
    Steger, G.
    Kwasny, W.
    Dubsky, P.
    Selim, U.
    Fitzal, F.
    Hochreiner, G.
    Wette, V.
    Sevelda, P.
    Ploner, F.
    Bartsch, R.
    Fesl, C.
    Greil, R.
    ANNALS OF ONCOLOGY, 2015, 26 (02) : 313 - 320
  • [24] Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor-Positive Breast Cancer (E-3193, INT-0142): A Trial of the Eastern Cooperative Oncology Group
    Tevaarwerk, Amye J.
    Wang, Molin
    Zhao, Fengmin
    Fetting, John H.
    Cella, David
    Wagner, Lynne I.
    Martino, Silvana
    Ingle, James N.
    Sparano, Joseph A.
    Solin, Lawrence J.
    Wood, William C.
    Robert, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (35) : 3948 - U237
  • [25] Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: A report of the National Cancer Institute of Canada Clinical Trials Group
    Pritchard, KI
    Paterson, AHG
    Fine, S
    Paul, NA
    Zee, B
    Shepherd, LE
    AbuZahra, H
    Ragaz, J
    Knowling, M
    Levine, MN
    Verma, S
    Perrault, D
    Walde, PLD
    Bramwell, VHC
    Poljicak, M
    Boyd, N
    Warr, D
    Norris, BD
    Bowman, D
    Armitage, GR
    Weizel, H
    Buckman, RA
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) : 2302 - 2311
  • [26] Randomized phase III study of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients (pts) with stage III colon cancer (CC): Final results of Japan Clinical Oncology Group study (JCOG0205)
    Shimada, Yasuhiro
    Hamaguchi, Tetsuya
    Moriya, Yoshihiro
    Saito, Norio
    Kanemitsu, Yukihide
    Takiguchi, Nobuhiro
    Ohue, Masayuki
    Kato, Takeshi
    Takii, Yasumasa
    Sato, Toshihiko
    Tomita, Naohiro
    Yamaguchi, Shigeki
    Akaike, Makoto
    Mishima, Hideyuki
    Kubo, Yoshiro
    Mizusawa, Junki
    Nakamura, Kenichi
    Fukuda, Haruhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
    Mavroudis, D.
    Matikas, A.
    Malamos, N.
    Papakotoulas, P.
    Kakolyris, S.
    Boukovinas, I.
    Athanasiadis, A.
    Kentepozidis, N.
    Ziras, N.
    Katsaounis, P.
    Saloustros, E.
    Georgoulias, V.
    ANNALS OF ONCOLOGY, 2016, 27 (10) : 1873 - 1878
  • [28] Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients:: results of French Adjuvant Study Group 02 and 07 trials
    Namer, M
    Fargeot, P
    Roché, H
    Campone, M
    Kerbrat, P
    Romestaing, P
    Monnier, A
    Luporsi, E
    Montcuquet, P
    Bonneterre, J
    ANNALS OF ONCOLOGY, 2006, 17 (01) : 65 - 73
  • [29] Phase III trial comparing 4-cycle doxorubicin plus cyclophosphamide followed by 4-cycle taxan with 8-cycle taxan as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02 trial
    Watanabe, T.
    Kuranami, M.
    Inoue, K.
    Masuda, N.
    Aogi, K.
    Iwata, H.
    Mukai, H.
    Tanaka, S.
    Yamaguchi, T.
    Ohashi, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel
    Liu, Minetta C.
    Demetri, George D.
    Berry, Donald A.
    Norton, Larry
    Broadwater, Gloria
    Robert, Nicholas J.
    Duggan, David
    Hayes, Daniel F.
    Henderson, I. Craig
    Lyss, Alan
    Hopkins, Judith
    Kaufman, Peter A.
    Marcom, P. Kelly
    Younger, Jerry
    Lin, Nancy
    Tkaczuk, Katherine
    Winer, Eric P.
    Hudis, Clifford A.
    CANCER TREATMENT REVIEWS, 2008, 34 (03) : 223 - 230
123